Twist Bioscience Stock Price, News & Analysis

Twist Bioscience (NASDAQ: TWST) reported record revenues of $48.1 million for 2QFY22, a 54% increase from the previous year. Orders rose 32% to $55.0 million.

Despite a significant net loss of $60.7 million ($1.13 per share), the company maintained a strong cash position of $604.4 million. New partnerships and expanded product offerings, including a four-year agreement with Ginkgo Bioworks worth $58 million, highlight ongoing growth potential in the synthetic biology and data storage sectors.

Twist Bioscience (NASDAQ: TWST) recently announced six poster presentations at the PEGS Summit in Boston from May 2-6. The presentations focus on the company's advancements in antibody discovery and library construction capabilities, particularly for high-impact targets. Notable sessions include 'Writing the Future of Biologics' by Aaron Sato on May 2 and 'Rapid, Function-Forward mAb Discovery' by Tracey Mullen on May 4. These initiatives aim to enhance the development of therapies like CAR-T cell treatments.

Twist Bioscience Corporation has launched a new High Throughput Antibody Production platform that streamlines the process of generating purified antibodies from digital DNA sequences. This innovation is designed to alleviate bottlenecks in antibody discovery, enhancing efficiency in therapeutic screening. Customers can order antibody sequences through Twist's platform, which employs bioinformatics to filter viable sequences, allowing for the simultaneous production of thousands of distinct antibodies. Deliveries are typically made within 35 business days.

Twist Bioscience Corporation (NASDAQ: TWST) has joined the Storage Networking Industry Association (SNIA) as a voting member. This involvement aims to enhance data protection technology awareness and explore standards for DNA as a long-term data storage medium. SNIA emphasizes the importance of developing vendor-neutral architectures and standards in the storage industry. Twist engages actively to guide the implementation of these new standards, which can potentially impact data storage methods in various sectors, including healthcare and industrial research.

Twist Bioscience (NASDAQ: TWST) has announced the promotion of Tracey Mullen to Senior Vice President of Operations and Nimisha Srivastava to Senior Vice President of Research and Development. This follows the departure of Patrick Weiss from his role as Chief Operating Officer to a strategic advisor position, effective April 21, 2022. Mullen brings extensive experience from her previous role as CEO of Abveris, while Srivastava has been pivotal in automating laboratory processes since joining Twist in 2014. The company continues its growth trajectory in synthetic biology.

Twist Bioscience Corporation (NASDAQ: TWST) will release its financial results for Q2 fiscal 2022, ending March 31, 2022, on May 5, 2022, after market close. A conference call for analysts and investors is scheduled for 4:30 p.m. ET to discuss these results and provide a business update. The press release will be available on their website ahead of the call. Twist specializes in synthetic DNA production, utilizing a unique silicon-based technology to manufacture synthetic DNA products for various industries, including healthcare and agriculture.

Twist Bioscience (NASDAQ: TWST) and MediSix Therapeutics have announced a collaboration to discover novel antibodies against five undisclosed targets. Twist will utilize its proprietary Library of Libraries for antibody discovery, while MediSix will develop CAR T-cell therapies for T-cell malignancies and autoimmune diseases. Twist is set to receive an upfront payment and may earn milestone payments and royalties on future sales. This partnership aims to address challenges in treating T-cell cancers and expands Twist's global footprint, particularly in the Asia Pacific region.

Twist Bioscience Corporation (NASDAQ: TWST) and Ginkgo Bioworks (NYSE: DNA) announced a new four-year supply agreement, enhancing their collaboration in synthetic biology. This agreement marks an increase in Ginkgo's commitments to purchase synthetic DNA from Twist to support its growth across various industries, including vaccine manufacturing and agriculture. The partnership builds on a previous agreement from 2017, highlighting a significant order of approximately one billion base pairs of synthetic DNA.

Twist Bioscience Corporation (NASDAQ: TWST) has launched synthetic RNA positive controls for SARS-CoV-2, encapsulated in proprietary stainless steel minicapsules from Imagene SA. These minicapsules provide a stable, cost-effective solution for shipping and storing fragile RNA at room temperature, overcoming cold chain limitations. This product aims to facilitate COVID-19 monitoring in regions lacking adequate storage facilities. The launch builds on a 2019 partnership with Imagene, enhancing Twist's capabilities in supplying stable RNA and DNA products globally.